Comparative Pharmacology
Head-to-head clinical analysis: CABOZANTINIB versus LAPATINIB DITOSYLATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CABOZANTINIB versus LAPATINIB DITOSYLATE.
CABOZANTINIB vs LAPATINIB DITOSYLATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Small molecule tyrosine kinase inhibitor that targets MET, VEGFR2, RET, AXL, KIT, TIE2, FLT3, and TRKB. Inhibits tumor growth, angiogenesis, and metastasis.
Reversible tyrosine kinase inhibitor that inhibits ErbB-1 (EGFR) and ErbB-2 (HER2) by binding to the ATP-binding pocket, preventing receptor autophosphorylation and downstream signaling.
60 mg orally once daily, taken without food (at least 1 hour before or 2 hours after eating).
Lapatinib ditosylate 1250 mg orally once daily on days 1-21 continuously, plus capecitabine 2000 mg/m2 orally once daily in 2 divided doses on days 1-14 of a 21-day cycle. Alternatively, 1500 mg orally once daily with letrozole 2.5 mg orally once daily continuously.
None Documented
None Documented
Clinical Note
moderateCabozantinib + Digoxin
"Cabozantinib may decrease the cardiotoxic activities of Digoxin."
Clinical Note
moderateCabozantinib + Digitoxin
"Cabozantinib may decrease the cardiotoxic activities of Digitoxin."
Clinical Note
moderateCabozantinib + Deslanoside
"Cabozantinib may decrease the cardiotoxic activities of Deslanoside."
Clinical Note
moderateCabozantinib + Acetyldigitoxin
"Cabozantinib may decrease the cardiotoxic activities of Acetyldigitoxin."
Terminal elimination half-life is approximately 99 hours (range 68–136 hours) in patients with advanced solid tumors, supporting once-daily dosing.
Terminal elimination half-life is 14–24 hours; after repeated dosing, effective half-life is ~24 hours clinically.
Primarily fecal (approximately 54% of administered dose as unchanged drug and metabolites), with renal excretion accounting for approximately 27% (largely as metabolites). Mean total recovery in feces and urine is about 81%.
Fecal (approximately 87% as metabolites, with 3% as parent drug); renal (approximately 3% as metabolites).
Category C
Category C
Tyrosine Kinase Inhibitor
Tyrosine Kinase Inhibitor